Andrew Ricci
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Andrew Ricci has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Patricia DeFusco
Hartford Hospital, Hartford, CT 06102
2 shared publications - Quing Zhu
Department of Biomedical Engineering Washington University in St. Louis St. Louis Missouri USA
2 shared publications - Susan Tannenbaum
Neag Comprehensive Cancer Center, University of Connecticut Health Center, Farmington, CT
2 shared publications Alex Merkulov
University of Connecticut Health Center, Farmington, CT 06030
1 shared publicationChen Xu
University of Connecticut, Storrs, CT 06269
1 shared publicationFeifei Zhou
University of Connecticut, Storrs, CT 06269
1 shared publication
Latest Publications
- 1 January 2018
- Published by Optica Publishing Group
- p. OTh4D.2
Identifying an Optimal Time Window for Predicting Response to Neoadjuvant Chemotherapy Using Breast Cancer Subtypes and Hemoglobin Parameters Assessed by US-guided Optical Tomography
The study has identified an optimal time window for predicting breast cancer pathological response to neoadjuvant chemotherapy (NAC) based on tumor subtypes, pretreatment total-hemoglobin level and early changes of total-hemoglobin following NAC.
- 1 January 2018
- Published by Optica Publishing Group
- p. OTh4D.2
Identifying an Optimal Time Window for Predicting Response to Neoadjuvant Chemotherapy Using Breast Cancer Subtypes and Hemoglobin Parameters Assessed by US-guided Optical Tomography
The study has identified an optimal time window for predicting breast cancer pathological response to neoadjuvant chemotherapy (NAC) based on tumor subtypes, pretreatment total-hemoglobin level and early changes of total-hemoglobin following NAC.
- Open Access
- 28 October 2014
- Published by Springer Nature in Breast Cancer Research
- Vol. 16 (5) , 456
Pathologic response prediction to neoadjuvant chemotherapy utilizing pretreatment near-infrared imaging parameters and tumor pathologic criteria
Introduction: The purpose of this study is to develop a prediction model utilizing tumor hemoglobin parameters measured by ultrasound-guided near-infrared optical tomography (US-NIR) in conjunction with standard pathologic tumor characteristics to predict pathologic response before neoadjuvant chemotherapy (NAC) is given. Methods: Thirty-four patients’ data were retrospectively analyzed using a multiple logistic regression model to predict response. These patients were split into 30 groups of training (24 tumors) and testing (12 tumors) for cross validation. Tumor vascularity was assessed using US-NIR measurements of total hemoglobin (tHb), oxygenated (oxyHb) and deoxygenated hemoglobin (deoxyHb) concentrations acquired before treatment. Tumor pathologic variables of tumor type, Nottingham score, mitotic index, the estrogen and progesterone receptors and human epidermal growth factor receptor 2 acquired before NAC in biopsy specimens were also used in the prediction model. The patients’ pathologic response was graded based on the Miller-Payne system. The overall performance of the prediction models was evaluated using receiver operating characteristic (ROC) curves. The quantitative measures were sensitivity, specificity, positive and negative predictive values (PPV and NPV) and the area under the ROC curve (AUC). Results: Utilizing tumor pathologic variables alone, average sensitivity of 56.8%, average specificity of 88.9%, average PPV of 84.8%, average NPV of 70.9% and average AUC of 84.0% were obtained from the testing data. Among the hemoglobin predictors with and without tumor pathological variables, the best predictor was tHb combined with tumor pathological variables, followed by oxyHb with pathological variables. When tHb was included with tumor pathological variables as an additional predictor, the corresponding measures improved to 79%, 94%, 90%, 86% and 92.4%, respectively. When oxyHb was included with tumor variables as an additional predictor, these measures improved to 77%, 85%, 83%, 83% and 90.6%, respectively. The addition of tHb or oxyHb significantly improved the prediction sensitivity, NPV and AUC compared with using tumor pathological variables alone. Conclusions: These initial findings indicate that combining widely used tumor pathologic variables with hemoglobin parameters determined by US-NIR may provide a powerful tool for predicting patient pathologic response to NAC before the start of treatment. Trial registration: ClincalTrials.gov ID: NCT00908609 (registered 22 May 2009)
- 28 October 2014
- Published by Springer Nature in Breast Cancer Research
- Vol. 16 (5) , 456
Open AccessPathologic response prediction to neoadjuvant chemotherapy utilizing pretreatment near-infrared imaging parameters and tumor pathologic criteria
Introduction: The purpose of this study is to develop a prediction model utilizing tumor hemoglobin parameters measured by ultrasound-guided near-infrared optical tomography (US-NIR) in conjunction with standard pathologic tumor characteristics to predict pathologic response before neoadjuvant chemotherapy (NAC) is given. Methods: Thirty-four patients’ data were retrospectively analyzed using a multiple logistic regression model to predict response. These patients were split into 30 groups of training (24 tumors) and testing (12 tumors) for cross validation. Tumor vascularity was assessed using US-NIR measurements of total hemoglobin (tHb), oxygenated (oxyHb) and deoxygenated hemoglobin (deoxyHb) concentrations acquired before treatment. Tumor pathologic variables of tumor type, Nottingham score, mitotic index, the estrogen and progesterone receptors and human epidermal growth factor receptor 2 acquired before NAC in biopsy specimens were also used in the prediction model. The patients’ pathologic response was graded based on the Miller-Payne system. The overall performance of the prediction models was evaluated using receiver operating characteristic (ROC) curves. The quantitative measures were sensitivity, specificity, positive and negative predictive values (PPV and NPV) and the area under the ROC curve (AUC). Results: Utilizing tumor pathologic variables alone, average sensitivity of 56.8%, average specificity of 88.9%, average PPV of 84.8%, average NPV of 70.9% and average AUC of 84.0% were obtained from the testing data. Among the hemoglobin predictors with and without tumor pathological variables, the best predictor was tHb combined with tumor pathological variables, followed by oxyHb with pathological variables. When tHb was included with tumor pathological variables as an additional predictor, the corresponding measures improved to 79%, 94%, 90%, 86% and 92.4%, respectively. When oxyHb was included with tumor variables as an additional predictor, these measures improved to 77%, 85%, 83%, 83% and 90.6%, respectively. The addition of tHb or oxyHb significantly improved the prediction sensitivity, NPV and AUC compared with using tumor pathological variables alone. Conclusions: These initial findings indicate that combining widely used tumor pathologic variables with hemoglobin parameters determined by US-NIR may provide a powerful tool for predicting patient pathologic response to NAC before the start of treatment. Trial registration: ClincalTrials.gov ID: NCT00908609 (registered 22 May 2009)